Lamivudine/tenofovir
(Redirected from
Lamivudine/tenofovir disoproxil
)
 |
Nucleotide reverse transcriptase inhibitor | |
| Clinical data | |
|---|---|
| Trade names | Cimduo, Temixys |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618039 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a
antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).[1][3] It contains lamivudine and tenofovir disoproxil.[1] It is taken by mouth.[1]
Lamivudine/tenofovir was approved for medical use in the United States in February 2018.[1][4]
References
- ^ a b c d e "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Retrieved 26 March 2020.
- ^ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 13 February 2022.
- PMID 33598310.
- ^ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Retrieved 26 March 2020.
Further reading
- "WHO Public Assessment Report: HA414 - Lamivudine/Tenofovir disoproxil fumarate - 300mg/300mg - Tablets - Mylan Laboratories Ltd - India". World Health Organization (WHO). Archived from the original on 26 March 2020.
External links
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.
